Chinese expert consensus on whole-process management of oxaliplatin-induced hypersensitivity reactions (2024 edition)

Oxaliplatin serves as a basic therapeutic agent for various malignant tumors. Oxaliplatin-induced hypersensitivity reactions are potentially life-threatening, and frequently lead to treatment discontinuation. Alternative therapies may be less effective and/or more expensive, with varying tolerability. Oxaliplatin hypersensitivity reactions typically manifest as a classic type Ⅰ allergy, as well as cytokine release reactions and mixed types. In clinical practice, management of anaphylaxis and questions relative to rechallenge with oxaliplatin after occurrence of hypersensitivity reactions are of utmost concern. Therefore, based on evidence-based medicine and clinical practice experience, the expert panel carried out a comprehensive assessment and discussion on the definition, clinical characteristics, diagnosis, classification and grading criteria, management, and rechallenge of hypersensitivity reactions to oxaliplatin. Eventually, the "Chinese expert consensus on whole-process management of oxaliplatin-induced hypersensitivity reactions (2024 edition)" was formulated to further standardize the whole-process management of oxaliplatin-induced hypersensitivity reactions. The consensus has been registered on Practice guideline REgistration for transPAREncy (PREPARE) with the registration number PREPARE-2024CN371.